Celltaxis

Celltaxis is a biotechnology company focused on enhancing the precision and efficacy of cell-based therapies through advanced cell-trafficking technology. The company's proprietary platform is designed to engineer therapeutic cells, such as mesenchymal stem cells (MSCs) and immune cells, to improve their ability to home and extravasate into target tissues like solid tumors and sites of inflammation. By overcoming the biological barriers that typically limit cell therapy delivery, Celltaxis aims to maximize therapeutic impact while minimizing off-target effects. The company's initial pipeline targets high-unmet-need areas, including glioblastoma and other aggressive cancers. Based on research from Harvard Medical School and Massachusetts General Hospital, the technology leverages natural homing mechanisms to ensure therapeutic payloads reach their intended destination.